Glatiramer acetate controlled release - Mapi Pharma

Drug Profile

Glatiramer acetate controlled release - Mapi Pharma

Alternative Names: GA Depot; GA long-acting injection; Glatiramer acetate depot formulation - Mapi Pharma; Glatiramer acetate long-acting formulation - Mapi Pharma; Glatiramer acetate microspheres

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Mapi Pharma
  • Class Peptides; Polymers
  • Mechanism of Action MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Israel (SC, Controlled release)
  • 16 Dec 2015 Glatiramer acetate controlled release - Mapi Pharma is available for licensing in World as of 16 Dec 2015.
  • 01 Oct 2014 Phase-II clinical trials in Multiple sclerosis (Recurrent) in Israel (IM) (NCT02212886)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top